# Sapropterin dihydrochloride

MedChemExpress

®

| Cat. No.:          | HY-A0124A  |               |
|--------------------|--|---------------|
| CAS No.:           | 69056-38-8   | H H<br>.NNNH2 |
| Molecular Formula: | C <sub>9</sub> H <sub>17</sub> Cl <sub>2</sub> N <sub>5</sub> O <sub>3</sub>     | QH THE        |
| Molecular Weight:  | 314.17   |               |
| Target:            | Others   | он н о        |
| Pathway:           | Others   | H–Cl          |
| Storage:           | 4°C, stored under nitrogen, away from moisture                                   | H–CI          |
|                    | * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from |               |
|                    | moisture)  |               |

### SOLVENT & SOLUBILITY

| In Vitro | DMSO : ≥ 200 mg/mL<br>H <sub>2</sub> O : 100 mg/mL (31<br>* "≥" means soluble, | DMSO : ≥ 200 mg/mL (636.60 mM)<br>H <sub>2</sub> O : 100 mg/mL (318.30 mM; Need ultrasonic)<br>* "≥" means soluble, but saturation unknown. |               |            |            |  |
|----------|--|---|---------------|------------|------------|--|
|          |  | Solvent Mass<br>Concentration   | 1 mg          | 5 mg       | 10 mg      |  |
|          | Preparing<br>Stock Solutions   | 1 mM  | 3.1830 mL     | 15.9150 mL | 31.8299 mL |  |
|          | Stock Solutions  | 5 mM  | 0.6366 mL     | 3.1830 mL  | 6.3660 mL  |  |
|          |  | 10 mM   | 0.3183 mL     | 1.5915 mL  | 3.1830 mL  |  |
|          | Please refer to the solubility information to select the appropriate solvent.  |   |               |            |            |  |
| In Vivo  | 1. Add each solvent<br>Solubility: 100 m                                       | one by one: PBS<br>z/mL (318.30 mM); Clear solution; Net  | ed ultrasonic |            |            |  |

| DIOLOGICAL ACTIVI |   |
|-------------------|---|
| Description       | Sapropterin ((6R)-BH4) is an orally active phenylalanine hydroxylase (PAH) cofactor, which is effective in reducing blood phenylalanine concentrations. Sapropterin also drives autoimmunity. Sapropterin can be used in study of phenylketonuria (PKU) <sup>[1][2]</sup> . |
| In Vivo           | Sapropterin (2 mg/kg/d, p.o., 19 d) aggravates experimental autoimmune encephalomyelitis (EAE) in mice <sup>[2]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |

## CUSTOMER VALIDATION

- Mol Cell. 2020 Jan 2;77(1):95-107.e5.
- Mol Cell. 2020 Jan 2;77(1):95-107.e5.

See more customer validations on <u>www.MedChemExpress.com</u>

### REFERENCES

[1]. Sanford M, et al. Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia. Drugs. 2009;69(4):461-76.

[2]. Schmitz K, et al. Sapropterin (BH4) Aggravates Autoimmune Encephalomyelitis in Mice. Neurotherapeutics. 2021 Jul;18(3):1862-1879.

#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA